OCULAR THERAPEUTIX, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
OCULAR THERAPEUTIX, INC (OCUL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $18.38 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $18.38M, a 65.54% increase from fiscal 2024.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $11.10M, a 3937.09% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $275.00K, a 47.85% increase from fiscal 2022.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $186.00K, a 97.26% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2025-12-31 | $18.38M 10-K · filed 2026-02-05 |
| 2024-12-31 | $11.10M 10-K · filed 2026-02-05 |
| 2023-12-31 | $275.00K 10-K · filed 2026-02-05 |
| 2022-12-31 | $186.00K 10-K · filed 2025-03-03 |
| 2021-12-31 | $6.78M 10-K · filed 2024-03-11 |
| 2020-12-31 | $4.31M 10-K · filed 2023-03-06 |
| 2019-12-31 | $54.00K 10-K · filed 2022-02-28 |
| 2018-12-31 | $551.00K 10-K · filed 2020-03-12 |
| 2017-12-31 | $408.00K 10-K · filed 2020-03-12 |
| 2016-12-31 | $575.00K 10-K · filed 2019-03-07 |
| 2015-12-31 | $3.19M 10-K · filed 2018-03-08 |
| 2014-12-31 | $323.00K 10-K · filed 2017-03-10 |
| 2013-12-31 | $38.00K 10-K · filed 2016-03-10 |
| 2012-12-31 | $6.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |